|
KMID : 0882420090770060713
|
|
Korean Journal of Medicine
2009 Volume.77 No. 6 p.713 ~ p.715
|
|
|
Lamivudine and adefovir combination therapy in lamivudine-resistant HBeAg-positive chronic hepatitis B patients
|
|
Lee Han-Chu
|
|
|
Abstract
|
|
|
|
The introduction of lamivudine (LAM) has opened a new era for the treatment of chronic hepatitis B (CHB). However, the major drawback of LAM, which currently limits its use as first-line therapy, is the high rate of occurrence of drug resistance. In patients with LAM-resistant CHB, recent long-term findings have indicated that adding adefovir (ADV) to ongoing LAM therapy was more beneficial than switching to ADV alone, because the former showed a diminished rate of resistance to ADV with a well-tolerated safety profile. Above all, the most important strategy for CHB treatment must be to use a potent first-line antiviral with high genetic barriers to resistance in order to prevent the development of multidrug resistance.
|
|
|
KEYWORD
|
|
|
Chronic hepatitis B, Drug resistance, Lamivudine, Adefovir
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|